Note 4 - Equity Method Investment (Tables)

12 Months Ended

Dec. 31, 2025

Assets:
Current assets:
Cash	$	16,479
Prepaid expenses, deposits, and other current assets		3,474
Total current assets		19,953
Fixed assets, net		964
Operating lease right-of-use assets		2,871
Intangible assets, net		877
Other assets		379
Total assets		25,044
Liabilities:
Current liabilities:
Accounts payable		1,069
Accrued expenses and other current liabilities		1,674
Operating lease liabilities, current portion		865
Senior Secured Convertible Notes - at fair value		10,268
Total current liabilities		13,876
Operating lease liabilities, less current portion		2,011
Total liabilities		15,887
Net Assets of Lucid Diagnostics at September 10, 2024	$	9,157

Investment in former Consolidated Subsidiary (Fair Value of Lucid common stock)	$	25,105
Add: Noncontrolling interest - Lucid		56,339
Less: Net Assets of Former Consolidated Subsidiary - Lucid		(9,157	)
Gain on Deconsolidation of Lucid	$	72,287

	*December 31, 2025*		*December 31, 2024*
Cash	$	34,705	$	22,358
Other current assets		2,763		2,790
Non-current assets		2,977		5,567
Total assets		40,445		30,715
Current liabilities		28,582		23,524
Non-current liabilities		927		1,800
Shareholders’ equity		10,936		5,391
Total liabilities and stockholders’ equity	$	40,445	$	30,715

PAVmed Inc. 10-K